Establishment Labs Holdings Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067
The investigation focuses on Establishment Labs’ repeated claims that its breast implants are safer than those of its competitors due to “rigorous science” and “clinical data.”
On Oct. 19, 2022 Establishment Labs’ claims came into question, when analyst Hindenburg Research published a scathing report entitled “Establishment Labs: A Financially Stretched Silicon Safety Charade.” Hindenburg accuses the company about misleading investors about safety claims, concluding in part: (1) “almost all key safety studies touted by the company have undisclosed or under-disclosed conflicts of interest;” (2) “Australian and French authorities expressed concerns with the company’s data with Australian regulators calling the company’s main safety data ‘observational uncontrolled studies;'” (3) “[t]he advisor Establishment just hired to support its U.S. launch was sued by the SEC in 2018 for fraudulently lying then destroying records that concealed regulatory and safety issues with breast implants;” and (4) “records show Establishment ships products to entities formerly owned by the CEO and his family, raising questions of conflicts of interest.”
In response, the price of Establishment Labs shares closed sharply lower on Oct. 19, wiping out more than $100 million of shareholder value.